Saturday, February 16, 2019
Home Research & Development

Research & Development

Killing Cancer Cells by Shining a Light on a Rare Metal

Iridium –  a very hard, brittle, second-densest silvery-white transition metal of the platinum group, is a found in meteorites in a much higher abundance than in the Earth's crust. As a result, the unusually high abundance of iridium in the clay layer at the Cretaceous–Paleogene boundary resulted in the Alvarez hypothesis, which suggest that the impact of a massive extraterrestrial...

Studies on Origins of Colon Cancer may Lead to New and More Effective Therapies

Senior Research Scientist Bruce Boman, MD, Ph.D., MSPH, FACP, at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System in Wilmington, DE , has received a U.S. $ 916,577 grant from the Lisa Dean Moseley Foundation to further stem cell research into the origins of colon cancer. Funding research and clinical programs undertaken by qualified...

Electromagnetic Navigation Bronchoscopy Shows Positive Response In Lung Cancer Study

An analysis of 12-month results from NAVIGATE, the largest, prospective, multicenter trial designed to evaluate outcomes following electromagnetic navigation bronchoscopy™ (ENB™) procedures using Medtronic's superDimension™ navigation system, shows positive results. Electromagnetic navigation bronchoscopy™ is a minimally invasive technology that guides endoscopic tools to pulmonary lesions.  The technology has been evaluated primarily in small, single-center studies. NAVIGATE enrolled subjects at 37...

Scientists Discover Possible way to Make Resistant Melanomas Susceptible to Immunotherapy

Researchers at the Ludwig Cancer Research Institute,  an international community of scientists focused on cancer research, with headquarters in New York City, NY and Zürich, Switzerland, have uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies. The study, led by Ping-Chih Ho of the Lausanne Branch of...

Minimally Invasive Endoscopy Tool may Change Treatment for Pancreatic Cancer Patients

A minimally invasive treatment option may change treatment options for patients with pancreatic cancer. The development of significantly more effective treatment options is possible as a result of an endoscopy tool created by a team at the Penn State Department of Mechanical Engineering. The location of the pancreas in the abdomen and the difficulty to detect the disease make it...

Study Shows How Molecular Profiling may Help Catch Lung Cancer Early, Leading to New Treatments

The world's first genetic sequencing of precancerous lung lesions, referred to as lung carcinoma in situ (CIS) are the preinvasive precursor to squamous cell carcinoma and could pave the way for very early detection and new treatments. A new study published in Nature Medicine by researchers from University College London (UCL) describes the cellular basis of a previously unknown clinical...

Trifluridine/tipiracil Significantly Improved Overall Survival versus Placebo in Gastric Cancer

The safety and efficacy of trifluridine/tipiracil (Lonsurf®; Taiho Oncology/Taiho Pharmaceutical and Servier) in patients who had undergone gastrectomy, the surgical removal of a part or the whole of the stomach, as part of their treatment for metastatic gastric cancer (mGC), are consistent with the overall study results published in The Lancet Oncology. Lonsurf® consists of a thymidine-based nucleoside analog, trifluridine,...

FDA Accepts sBLA for Atezolizumab + Abraxane and Carboplatin for Metastatic Non-squamous NSCLC

The United States Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Roche/Genentech) in combination with albumin-bound paclitaxel or nab-paclitaxel (Abraxane®; Abraxis Bioscience/Celgene) and carboplatin (Pfizer/Hospira) for the initial, first-line, treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations. Atezolizumab is...

Neoleukin-2/15 – A Novel Immunotherapy Agent Designed to Avoid Common Side Effects

Scientists at the University of Washington Medicine's Institute for Protein Design (IPD) in Seattle, Washington, have created a new protein that mimics the action of a key immune regulatory protein, interleukin 2 (IL-2). In the development of the new protein, the scientists used a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but...

A Compound Being Developed to Treat an Eye Disease may also Kill Leukemia Cells

An active ingredient in eye drops called SPHINX31, being developed for the treatment of a form of eye disease, has shown promise for treating an aggressive form of blood cancer called Acute Myeloid Leukemia or AML. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential...

right side

ads

Related articles